当前位置: X-MOL 学术Cell › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Selection of epigenetically privileged HIV-1 proviruses during treatment with panobinostat and interferon-α2a
Cell ( IF 64.5 ) Pub Date : 2024-02-17 , DOI: 10.1016/j.cell.2024.01.037
Marie Armani-Tourret , Ce Gao , Ciputra Adijaya Hartana , WeiWei Sun , Leah Carrere , Liliana Vela , Alexander Hochroth , Maxime Bellefroid , Amy Sbrolla , Katrina Shea , Theresa Flynn , Isabelle Roseto , Yelizaveta Rassadkina , Carole Lee , Francoise Giguel , Rajeev Malhotra , Frederic D. Bushman , Rajesh T. Gandhi , Xu G. Yu , Daniel R. Kuritzkes , Mathias Lichterfeld

In a human clinical trial, combined treatment with the histone deacetylase inhibitor panobinostat and pegylated interferon-α2a increased the immunological vulnerability of HIV-1 reservoir cells and amplified naturally occurring immune selection pressure against HIV-1 proviruses integrated in permissive chromatin locations.

中文翻译:

在帕比司他和干扰素-α2a 治疗期间选择表观遗传特有的 HIV-1 原病毒

在一项人体临床试验中,组蛋白脱乙酰酶抑制剂帕比司他和聚乙二醇化干扰素-α2a联合治疗增加了HIV-1储存细胞的免疫脆弱性,并放大了针对整合在允许染色质位置的HIV-1原病毒的自然发生的免疫选择压力。
更新日期:2024-02-17
down
wechat
bug